News

Laparoscopic surgery cut length of hospital stay in colorectal cancer


 

FROM THE JOURNAL OF CLINICAL ONCOLOGY

In patients with colorectal cancer, laparoscopic resection reduced total hospital stay by a median of 2 days, compared with open surgery, researchers reported online May 5 in the Journal of Clinical Oncology.

However, laparoscopy did not significantly improve physical fatigue at 1 month, compared with open surgery, and it did not affect other secondary clinical outcomes, said Prof. Robin Kennedy of St. Mark’s Hospital, Harrow, England, and his associates.

The researchers conducted a multicenter, randomized trial of 204 patients with colorectal cancer, of whom 103 underwent laparoscopic resection and 101 had open surgery within a standardized enhanced recovery program (J. Clin. Oncol. 2014 May 5 [doi: 10.1200/JCO.2013.54.3694]).

Median total hospital stay was significantly shorter in the laparoscopy group (5 days; interquartile range, 4-9 days) vs. the open surgery group (7 days; IQR, 5-11 days; P = .033), the investigators reported. However, 1-month physical fatigue scores on the Multidimensional Fatigue Inventory 20 were similar between the two groups (mean for laparoscopy patients, 12.28; 95% confidence interval, 11.37-13.19; mean for open surgery patients, 12.05; 95% CI, 11.14-12.96; adjusted mean difference, –0.23; 95% CI, –1.52-1.07), the researchers reported. Other outcomes also were similar, including quality of the specimens based on central pathologic review, the researchers said.

The findings contradicted those of prior studies in which shorter duration of hospital stay correlated with less "pain, ileus, and other complications, leading to earlier mobilization, feeding, and recovery," the researchers noted. They recommended more studies to determine whether the similarities between other outcomes were due to a lack of power or truly indicated comparable short-term recoveries.

The research was funded by Cancer Research UK, the National Institute for Health Research, Ethicon Endo-Surgery Europe, the Medical Research Council ConDuCT Hub, and Yorkshire Cancer Research. The authors reported that they had no relevant conflicts of interest.

Recommended Reading

First SEER analysis including HER2 subtype is reported
MDedge Hematology and Oncology
Topical tazarotene did not improve response to imiquimod 5% in lentigo maligna
MDedge Hematology and Oncology
Polyp, adenoma detection rises with Endocuff device
MDedge Hematology and Oncology
Delaying ADT for PSA-only prostate cancer relapse appears safe
MDedge Hematology and Oncology
Obesity increased breast cancer mortality only in premenopausal women
MDedge Hematology and Oncology
Low-dose CT could up early lung cancer detection - at a price
MDedge Hematology and Oncology
Registry data: No increase in prostate cancer risk with long-term TRT
MDedge Hematology and Oncology
Midlife PSA measure predicted lethal prostate cancer
MDedge Hematology and Oncology
Pancreatic cancer predicted to become second-leading cause of U.S. cancer deaths by 2030
MDedge Hematology and Oncology
Clinical data support earlier PSA testing in black men
MDedge Hematology and Oncology